Bioshares have recently reported on AdAlta’s strategy update for its lead drug candidate AD-214 and plans for returning AD-214 to clinical studies.
The report covers the background on AdAlta’s 2021 announcement about plans to add an inhaled formulation for AD-214 to the existing intravenous route and the three keys reasons for the decision to prioritise the intravenous formulation for next clinical trials.
To read the report CLICK HERE.